Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Augmentation in OCD
NCT00318539Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Quetiapine + SRI with Placebo + SRI (2 arms). Primary endpoints: Change in Yale Brown Obsessive Compulsive Scale at 10 weeks and Number of responders at 10 weeks. Started Dec 2003; status: completed.
02
Drugs
quetiapine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT00318539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00318539.